Rezultati pretraživanja
  1. prije 3 sata

    Obseva Rating Lowered to Sell at Zacks Investment Research

  2. Obseva SA Given Consensus Recommendation of “Hold” by Brokerages

  3. prije 7 sati

    Obseva SA Receives Consensus Rating of “Hold” from Analysts

  4. Odgovor korisnicima
  5. prije 17 sati

    cheap valuation can be big winners in next 2 years

  6. prije 19 sati

    Added .. it’s breaking out

  7. prije 20 sati

    on the move.

  8. prije 20 sati

    Bought

  9. 5. velj
  10. 5. velj

    Obseva’s (NASDAQ:OBSV) “Buy” Rating Reiterated at Wedbush – Slater Sentinel

  11. 4. velj
  12. 3. velj
  13. 2. velj
  14. 1. velj

    let’s see those positive ph 3 results!!!

  15. 31. sij

    added at support level for long

  16. 29. sij

    As well if could beat on earnings I'd take it.

    Prikaži ovu nit
  17. 29. sij

    When will Wall Street start taking women’s health seriously? has a best in class drug to treat uterine fibroids with price targets at $1 billion plus...but has a market cap of $160 million.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.